|
Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24 percent reduction, while patients who took the 700 mg dose showed a 30 percent reduction compared to placebo. Psoriasis affects about 7.5 million people in the United States. There are currently a range of treatments to improve symptoms but no cure. The autoimmune disease market is currently dominated by injectable therapies. VTP-43742, which is a once-a-day oral drug, has the potential to treat other disorders such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseases, the company said. Psoriasis has been targeted as a promising treatment area by a number of drugmakers, including Novartis AG, which recently launched a product called Cosentyx (secukinumab) for the condition. This month, U.S. drugmaker AbbVie Inc bought marketing rights to a promising experimental psoriasis treatment from Germany's Boehringer Ingelheim for an initial upfront payment of $595 million.
23/03/2016 - Categoria: Farmaci - Da: Sh@wn - 402 letture
|